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Diabetes is a major health problem that is usually associated with obesity, together with hyperglycemia and increased advanced
glycation endproducts (AGEs) formation. Elevated AGEs elicit severe downstream consequences via their binding to receptors
of AGEs (RAGE). This includes oxidative stress and oxidative modifications of biological compounds together with heightened
inflammation. For example, albumin (major circulating protein) undergoes increased glycoxidation with diabetes and may
represent an important biomarker for monitoring diabetic pathophysiology. Despite the central role of adipose tissue in many
physiologic/pathologic processes, recognition of the effects of greater AGEs formation in this tissue is quite recent within the
obesity/diabetes context. This review provides a brief background of AGEs formation and adipose tissue biology and thereafter
discusses the impact of AGEs-adipocyte interactions in pathology progression. Novel data are included showing how AGEs
(especially glycated albumin) may be involved in hyperglycemia-induced oxidative damage in adipocytes and its potential links
to diabetes progression.
1. Introduction
Diabetes and associated pathologies are major health prob-
lemswith an existing high and continuously rising prevalence
worldwide. For example, more than 55 million individuals
are burdened with this condition in Europe with it being
projected to further increase to 64 million by 2030 [1].
Diabetes is a multifaceted disorder that is characterized by
various metabolic derangements, with hyperglycemia as a
major culprit. It is also associated with severe complica-
tions; for example, diabetes doubles the risk of developing
cardiovascular diseases (CVD) that currently constitute the
leading cause of mortality in developed countries [2]. Poor
lifestyle choices are strongly connected to diabetes devel-
opment, with especially suboptimal dietary intake and the
lack of exercise linked to obesity onset. The latter usually
includes excessive fat accumulation in adipose tissues, with
such persons exhibiting relatively high body mass index
(BMI) values of typically greater than 30 kg/m2. However,
obesity per se does not represent an underlying medical
condition but rather associated complications such as insulin
resistance, type 2 diabetes, and CVD [3]. For example, obese
persons with a BMI equal to 30 kg/m2 display a tenfold
increase in risk for developing obesity-related pathologies
compared to normal weight persons [4]. Together these
studies demonstrate that the tremendous increase in obesity
and associated pathologies (such as diabetes) constitute a
significant global burden of disease that requires serious
intervention strategies to counter its growing threat. In
addition, a greater understanding of underlying mechanisms
linking obesity to associated pathologies is essential as it may
lead to the development of novel therapeutic interventions.
Oxidative stress, and more specifically oxidative damage
to proteins, is increasingly thought to play a central, mech-
anistic role in this context as it is associated with modifica-
tions in the activities of biological compounds and cellular
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processes that may be linked to pathological complications.
In support, the pathophysiologic perturbations connected
with obesity-related diabetes are robustly associated with
hyperglycemia-induced oxidative stress [5, 6]. Here oxida-
tive stress may originate from various sources, with the
mitochondrion proposed to play a major role as what was
previously shown by our laboratory for the heart [7]. Further-
more, our recent data demonstrate that extra-mitochondrial
sources such as NADPH oxidases can also generate reactive
oxygen species (ROS) in cardiomyoblasts exposed to sim-
ulated hyperglycemic conditions [8]. Such oxidative stress
is further fueled by excessive ROS production from glucose
autoxidation and also the nonenzymatic, covalent attachment
of glucose molecules to circulating proteins that results in
the formation of glycated proteins and advanced glycation
endproducts (AGEs) [9]. Greater AGE availability can in
turn lead to downstream consequences, that is, binding to
the receptor for AGE (RAGE) on target cells that induces
several intracellular phenomena that likely contribute to the
onset of diabetic complications (recent review in [10]).Higher
systemic glucose levels can therefore lead to modifications of
target proteins with severe downstream effects. For example,
enhanced glycation of albumin (major protein in circulation)
with diabetes significantly impairs its normal antioxidant
function, while at the same time it also acquires additional
detrimental properties [11, 12].
Despite the pivotal part that adipocytes play in the onset
of several physiological/pathological processes, the role of
increased AGEs formation in such tissues is not well under-
stood and it is considered a slowly emerging research niche
area [13]. For example, the first studies showing the impact of
AGE-modified bovine serum albumin (BSA) on adipocytes
were only published in 2003 [14, 15]. This minireview will
therefore focus on the impact of AGEs-adipocyte interactions
in terms of diabetes pathology progression. The background
of AGEs formation and adipose tissue biology will initially be
reviewed and thereafter the focuswill shift to the link between
AGEs and adipocytes. We will also include recent data
focusing on glycated albumin and its link to hyperglycemia-
induced oxidative damage in adipocytes.
2. AGEs Formation and Receptors
Several reaction cascades can result in AGEs formation,
with the steps leading to glycation known as the Maillard
reaction that was discovered by the famous French chemist
Louis Camille Maillard during the early 1900s. This results in
the nonenzymatic and nonoxidative covalent attachment of
glucose molecules to target proteins, lipids, and nucleic acids
[16]. Glycoxidation refers to the radical-mediated oxidation
reaction of both free and protein-bound sugars [2]. The
Amadori rearrangement of glycated proteins gives rise to
advanced glycoxidation endproducts (also termed AGEs)
[17]. The high variety in such reactions renders AGEs a het-
erogeneous group of chemically modified proteins [13]. For
example, if lysine residues are particularly prone to glycation,
the reaction can also affect arginine and cysteine residues
leading to the generation of the major AGEs, that is, N𝜀-
(carboxymethyl)lysine (CML), the crosslinker pentosidine,
and S-(carboxymethyl)cysteine (CEC) [12] (Figure 1).
AGEs formation can result both from exogenous sources
(dietary intake) and also due to high glucose availability that
can trigger the Maillard reaction. AGEs were first identified
in food processing technology and used to improve its
quality in terms of taste, texture, and sensorial properties.
However, recent studies by the Vlassara laboratory revealed
the importance of dietary-related AGEs in the development
of metabolic disorders and uncovered a novel paradigm; that
is, AGEs can precede the onset of diabetes mellitus [18].
Interestingly, other exogenous AGEs sources have also been
identified; for example, it is found in cigarette smoke and as a
result smokers exhibit relatively high systemic levels [25].
What about AGEs formation within the in vivo context?
Such modifications occur on a much longer time scale
compared to exogenously supplied AGEs found in various
dietary and other sources. Thus in vivo glycation mainly
affects circulating proteins with a relatively long half-life such
as albumin, the most abundant plasma protein [12]. It is
also well established that enhanced albumin glycation with
diabetes is associated with the early occurrence of vascular
complications, together with functional protein alterations
[12, 26–28]. However, AGEs formation and accumulation
in diabetic individuals can result from various biochemical
reactions, that is, “many roads leading to Rome” [29]. Here
it can result from the reaction with highly reactive glucose-
derived glycolytic intermediates such as glyoxal, methylgly-
oxal, or 3-deoxyglucosone that react 7- to 200-fold faster
than glucose [19]. Of note, such AGEs are not formed solely
from carbohydrate metabolism but can also result from lipid
oxidation and degradation [20].
The glycation of plasma proteins leads to several down-
stream consequences and this is initiated by its binding to cell
membrane-specific receptors. The different receptors able to
recognize AGEs can be schematically divided into three types
depending on the signaling pathways subsequently induced
(Figure 2). RAGE represents the most studied receptor and
is mainly expressed on vascular, endothelial, and smooth
muscle cells and on monocyte/macrophage membranes [10,
30]. The RAGE family also includes the AGE-R complex
constituted by AGE-R1 80K-H, AGE-R2 OST-48, AGE-R3
galectin-3, SR-A (macrophage scavenger receptor types I and
II), and SR-B (SR-B type I and CD36) [23, 30]. Several
physiologic and pathophysiologic roles have been reported
for receptors able to bind toAGEs [10].Most are considered as
toxic effects, that is, downstream oxidative stress generation
and the initiation of inflammatory cascades such as ROS-
related activation of the proinflammatory transcriptional
modulator, NF𝜅B [10]. Conversely, AGE-R1 and R3 compete
with RAGE for AGE binding with resultant opposing effects
such as the protective role of AGER against ROS forma-
tion, oxidative stress, and increasing AGE degradation and
urinary excretion [18]. Scavenger receptors are a family of
receptors able to recognize oxidized or acetylated low density
lipoproteins at macrophage surfaces. Scavenger receptors A
and B (CD36 and SR-B, resp.) are involved in the intracellular
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Figure 1: Formation of AGEs. AGEs can have different origins such as rearrangements of Amadori products, the latter arising from the
glycation reaction. It can also be formed from glycolytic products with an exogenous origin. The glycation reaction mainly affects lysine,
arginine, and cysteine residues leading to the formation of the following major AGEs: N𝜀-(carboxymethyl)lysine (CML), the crosslinker
pentosidine, and S-(carboxymethyl)cysteine (CEC) (adapted from [10, 12, 13, 18–22]).
accumulation of cholesterol and the formation of foam cells
from macrophages in the early state of atherosclerosis [31].
As discussed in this section, AGEs have different origins
and several receptors play crucial roles in mediating their
downstream intracellular effects. In this regard several studies
focused on the effects of AGEs on vascular cells and also
circulating cells such as monocytes or circulation-derived
cells. However, despite the important role of adipocytes in the
etiology of diabetes, little is known about the effect of AGEs
on such cells. Thus in the following sections an overview of
adipose tissue biology and the impact of AGEs on adipocytes
will be discussed.
3. Overview of Adipose Tissue Biology
Obesity is defined as a condition characterized by exces-
sive fat accumulation and storage [32]. Hence, with caloric
abundance, fat is stored as triglycerides (TG) in adipocytes
within adipose depots. However, fat stores can also be utilized
during times of caloric debt to provide energy substrates by
the release of nonesterified fatty acids (NEFA) into circulation
[33]. With obesity there is a higher risk for the onset
of cardiometabolic diseases and here increased adiposity
(especially visceral adiposity) is linked with a greater risk
for insulin resistance/type 2 diabetes [34–36]. Although the
link(s) between obesity, insulin resistance, and the develop-
ment of type 2 diabetes is still not fully elucidated [33], several
studies show that the dysregulation of adipocyte function
is a crucial role player associated with diabetes pathology
progression. It is therefore not surprising that numerous
investigations are focusing on this problem in order to derive
novel therapies that target adipocyte dysregulation within the
diabetic milieu [37–39].
The underlying biology of adipose tissue is far more
complex than the original concept of its sole function being
that of a fat storage depot [40, 41]. In addition to TG
storage andNEFA release into circulation, adipocytes express
and secrete a variety of active biomolecules or “adipokines”
that regulate many physiologic processes such as insulin
sensitivity, appetite, immunity, and reproduction [42, 43].
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Figure 2: Different types of AGEs receptors. Three major AGEs-receptor pathways are represented: the AGE-R complex constituted by (a)
AGE-R1 80K-H, AGE-R2 OST-48, and AGE-R3 galectin-3, (b) RAGE, and (c) CD36 that belongs to SR-B (macrophage scavenger receptor
type B) (adapted from [10, 12, 23, 24]).
Although various processes are implicated in the develop-
ment of insulin resistance in adipocytes, inflammation and
oxidative stress emerge as robust causative factors in this
instance [6, 34, 44–46]. In support, a growing number of
publications highlight the role of inflammation and oxidative
stress and its impact on adipocyte disorders; for exam-
ple, recent work found increased NF𝜅B-mediated cytokine
release from adipocytes isolated from obese individuals
[47]. Growth hormone administration also improved glucose
intolerance in obese mice presumably by decreasing adipose
mass, oxidative stress, and chronic inflammation in visceral
fat stores [48]. Moreover, glutathionylated lipid aldehydes,
identified as products of adipocyte oxidative stress, result in
the activation of macrophage inflammation [49], while an
antioxidant molecule attenuated hypoxia-induced oxidative
stress, inflammation, and mitochondrial dysfunction in 3T3-
L1 adipocytes [50].
Among the cytokines originating from adipocytes, secre-
tion of the S100 calcium binding protein B, a RAGE ligand,
was recently shown to be enhanced in 3T3 L1 cells incubated
under inflammatory conditions and triggered macrophage
activation though RAGE [51].
Together these studies demonstrate that oxidative stress
and inflammation are crucial pathophysiologic mediators
that contribute to adipocyte dysregulation and the onset of
various cardiometabolic complications.
Most studies implicating oxidative stress and inflam-
mation in adipocyte pathophysiology employed in vitro-
based methodologies with cells exposed to various stressors
such as hypoxia, lipopolysaccharides, hydrogen peroxide, and
hyperglycemic treatments [52–55]. Thus limited studies have
examined the role of AGEs per se in adipocytes, with the
detrimental effects of AGEs generally investigated in vascular
cells and also circulating cells such as macrophages. The
following section will therefore focus on recent, novel data
regarding the impact of circulating AGEs on adipocytes.
4. AGEs Adipocyte Interactions and
the Onset of Pathologies
As discussed earlier, the effects of AGEs on adipocyte
function are limited; for example, a PubMed search with
the terms “AGEs adipocytes glycation” retrieved only 19
references. What then is known about the effects of AGEs on
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Figure 3:Adipocyte cell line expresses CD36 receptor. SW872 adipocytes were cultured on 12mm diameter poly(L-lysine) coverslips until 80%
confluency. Cells were fixed in diluted paraformaldehyde solution (4% v/v in PBS) at room temperature for 20min and stained successively
with a primary human CD36 antibody (1 : 50 in 1%PBS/BSA) for one hr, followed by incubation with an Alexa Fluor 488 goat anti-rabbit IgG
antibody (1 : 1,000) for 1 hr and with DAPI solution (1 : 1,000) for 10min (for staining of the nucleus). Cells were washed 3x in 1%PBS/BSA
between each step of different incubation periods. Cells were imaged using a Nikon eclipse microscope and NIS-Element software (Nikon
Corporation, Tokyo, Japan). ###𝑃 < 0.001 (vs.HSA) by Student’s unpaired 𝑡 test (𝑛 = 3).
adipocytes? Studies done thus far have identified the major
downstream effects as a heightened inflammatory response
as well as the generation of intracellular oxidative stress.
For example, a recent study showed that AGEs augmented
the expression of the prothrombotic/inflammatory regulator,
plasminogen activator inhibitor-1, in rat white adipocytes,
by a ROS-dependent pathway [56]. Moreover, glycated BSA
increased the adipogenic potential of senescent preadipocytes
(in vitro and ex vivo) via the AGEs-RAGE axis together
with an impairment of p53 function [57]. Here this occurs
by direct binding of RAGE to cytosolic p53 together with
the AGEs-RAGE suppression of p53 transcript levels. This
in turn enhances the adipogenic potential of preadipocytes,
with detrimental long-term effects. Recent experiments per-
formed in our laboratory demonstrated that glycated albu-
min exposure induced oxidative stress in primary human
adipocytes thereby leading to the accumulation of oxidized
proteins [58, 59]. A proteomic-based approach allowed us
to also determine preferential protein carbonylation targets
in human mature adipocytes treated with glycated versus
native albumin [59].Our studies also revealed greater insights
into some of the underlying mechanisms as AGEs-treated
adipocytes displayed decreased ubiquitin proteasomal system
(UPS) activities and were therefore unable to clear damaged
proteins. These data therefore suggest that the origin of
accumulated oxidized proteins in AGEs-treated adipocytes
likely stems from increased intracellular ROS production
together with an impaired UPS [59, 60].
What about the receptors for AGE found on adipocyte
membranes? Kuniyasu et al. (2003) were the first to dis-
cover the presence of CD36 on mouse adipocyte (3T3
L1 cell lines) cell membranes and on human adipocytes
from primary cultures that were able to bind and facilitate
AGEs endocytosis and degradation [15]. Two years later
the same group identified a pathological role for CD36 in
AGE binding in adipocytes, that is, resulting in decreased
in vivo leptin expression and attenuated insulin sensitivity
[61, 62]. In addition, adipocytes exposed to AGEs exhibited
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Figure 4: Glycated albumin induces CD36 expression in SW872 adipocytes. (a) SW872 adipocytes were incubated for 24 hr in the absence
(PBS) or the presence of 50 𝜇M native human serum albumin (HSA) or AGEs constituted by methylglyoxal- (MGO) modified HSA. The
relative quantification (% of fluorescent cells versus control PBS) of CD36 receptors was determined by employing a Becton Dickinson
FACScan (BD Biosciences, San Jose, CA) after staining with a primary human CD36 antibody (1 : 50) for 1 hr, followed by incubation with
the secondary Alexa Fluor 488 conjugated anti-rabbit (1 : 100) and PE-conjugated anti-mouse antibodies (1 : 100) for an additional hour. Cells
were washed with a 1% PBS/BSA blocking buffer between each incubation step. (b) For the CD36 Western blot, 20𝜇g proteins were isolated
from SW872 cell lysates (with different treatments as indicated), separated by SDS-PAGE, and transferred onto a nitrocellulose membrane
(Bio-Rad Laboratories, Hercules, CA) using a liquid transfer system. Membranes were soaked overnight with blocking buffer (PBS/0.1%
Tween/1%BSA) and subsequently incubated in blocking buffer with a primary humanCD36 antibody (1 : 200) for 2 hr, followed by incubation
with a secondary HRP-conjugated sheep anti-mouse IgG antibody (1 : 2,000). Membranes were washed with a blocking buffer (0.1% PBS/1%
Tween) between different incubation steps. Protein bands were detected by standard ECLmethods (Amersham Biosciences, Amersham, UK)
and visualized with a Kodak 2000R Image station (Eastman Kodak, Rochester, NY), and routine densitometric analysis was performed for
quantification.
diminished adiponectin expression (usually associated with
insulin resistance) [63]. AGEs exposure also caused impaired
functionality of adiponectin and this may further contribute
to the development of insulin resistance [64, 65].
The SW872 cell line has only recently been employed as
an adipocyte cell model [59, 66–68] and has the advantages
of a human origin and also does not require any incubation
cocktails to differentiate it into mature adipocytes [66]. We
therefore initiated studies using this cell line and found
elevated oxidative stress and protein damage in AGEs-treated
SW872 adipocytes. Such damaging effects could be blunted
with the co-treatment of nutritional antioxidants thereby
further implicating oxidative stress in this process [60, 69,
70]. Unpublished findings from our group also demonstrate,
for the first time as far as we are aware, that CD36 is expressed
in the SW872 cell line (Figure 3). Furthermore, fluorescence-
activated cell sorting (FACS) and Western blot data show
increased CD36 expression in SW872 adipocytes exposed to
glycated albumin purified from diabetic persons (Figure 4).
However, as there are no data regarding CD36 expression
in adipocytes within the diabetic context, further research
is needed. This is currently being pursued by our laboratory
in order to assess the correlation between AGEs levels and
CD36 expression in adipose tissues isolated from transgenic
diabetic mice (Db/Db strain).
5. Conclusions
Enhanced AGEs formation and the subsequent tissue and
cellular oxidative damage, together with inflammation, are
now well established in pathophysiologic disorder progres-
sion. Increasing evidence shows that AGEs accumulation in
adipose tissue may contribute to obesity-associated insulin
resistance. However, the precise nature and mechanisms of
AGEs impact on the adipocyte’s function are only now slowly
emerging and remain poorly understood. The picture is also
more complex than what was covered in this minireview,
focusing only on the role of circulating AGEs versus intra-
cellular AGEs in adipocytes. Moreover, the human body’s
defense mechanisms to counter the overproduction of AGEs
were not discussed in this paper.This field is a “hot topic” and
here dysregulation of the glyoxylase system, constituted by
glyoxylase-1 (GLO1) and glyoxylase II (GLO2), is emerging
as important contributors to higher AGEs levels [13]. For
example, a recent study established that GLO1 overexpression
attenuated AGEs and diminished oxidative stress [71]. Thus
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further research is required to gain greater insights into
the precise nature of the AGEs-RAGE axis in adipocytes
and its relevance within the diabetic milieu, with the focus
also on extra- and intracellular AGEs availability and the
glyoxylase defense system. Such novel insights may in turn
unlock novel pharmaceutical and/or nutritional strategic
developments that should help blunt obesity-related insulin
resistance progression.
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